Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Sotera Health Co paid$0 Mil more to buy back shares than it received from issuing new shares.
It spent$4 Mil paying down its debt.
It paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received$0 Mil from paying cash dividends to shareholders.
It spent$9 Mil on other financial activities.
In all, Sotera Health Cospent$13 Mil on financial activities for the
three
months ended in Mar. 2026.
Sotera Health Co (NAS:SHC) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Sotera Health Co's issuance of stock for the
three
months ended in Mar. 2026 was $0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Sotera Health Co's repurchase of stock for the
three
months ended in Mar. 2026 was $0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Sotera Health Co's net issuance of debt for the
three
months ended in Mar. 2026 was $-4 Mil.
Sotera Health Co spent$4 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Sotera Health Co's net issuance of preferred for the
three
months ended in Mar. 2026 was $0 Mil.
Sotera Health Co paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Sotera Health Co's cash flow for dividends for the
three
months ended in Mar. 2026 was $0 Mil.
Sotera Health Co received$0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Sotera Health Co's other financing for the
three
months ended in Mar. 2026 was $-9 Mil.
Sotera Health Co spent$9 Mil on other financial activities.
Sotera Health Co Cash Flow from Financing Related Terms
Sotera Health Co Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Sotera Health Co's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotera Health Co Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Sotera Health Co's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-105 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of $-105 Mil mean?
Sotera Health Co (SHC) has a Cash Flow from Financing of $-105 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Sotera Health Co and its competitors.
Is Sotera Health Co's Cash Flow from Financing too high?
Sotera Health Co's current Cash Flow from Financing is $-105 Mil. Overall, Sotera Health Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's Cash Flow from Financing compare to VCYT and RDNT?
Sotera Health Co's Cash Flow from Financing of $-105 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Diagnostics & Research company?
A good Cash Flow from Financing depends on the Medical Diagnostics & Research industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Sotera Health Co and its competitors. Sotera Health Co's current Cash Flow from Financing is $-105 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $16.35, compared to a current price of $18.42 — trading 12.7% above its estimated fair value. The current Cash Flow from Financing is $-105 Mil. Sotera Health Co's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Sotera Health Co (SHC), the current Cash Flow from Financing is $-105 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $18.42 is trading 12.7% above its estimated GF Value™ of $16.35.
GuruFocus considers Sotera Health Co to be Modestly Overvalued.
Key valuation signals for SHC:
Cash Flow from Financing: $-105 Mil
GF Value™: $16.35 vs. price of $18.42 (12.7% above fair value)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
73GF Score
Get the complete analysis for SHC
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
